Informed Consent for Coronary Angioplasty and Percutaneous Coronary Intervention (PCI)

Section 1info grid
Section 2text block
Section 3text block
Section 4list block
Section 5list block
Section 6text block
Section 7text block
Section 8text block
Section 9text block
Section 10text block
Section 11text block
Section 12text block
Section 13signature block

Informed Consent for Coronary Angioplasty and Percutaneous Coronary Intervention (PCI)

Patient and Procedure Identification

Nature and Purpose of the Procedure

Coronary angiography is a diagnostic procedure in which a flexible catheter is inserted through a peripheral artery (radial artery at the wrist, or femoral artery at the groin) and advanced under fluoroscopic (X-ray) guidance to the coronary arteries. Iodine-based contrast dye is injected to visualize the coronary anatomy and identify areas of narrowing or blockage. If a significant stenosis (typically greater than 70% luminal diameter reduction) is identified and deemed appropriate for intervention, percutaneous coronary intervention (PCI) is performed: a guidewire is crossed through the stenosis, a balloon catheter is inflated to compress the plaque, and a bare-metal or drug-eluting stent is deployed to scaffold the vessel wall and maintain patency. The entire procedure typically takes 30 to 90 minutes.

Critical Antiplatelet Compliance Requirement

Following drug-eluting stent (DES) implantation, dual antiplatelet therapy (DAPT) with aspirin (75-100 mg daily) and a P2Y12 inhibitor (clopidogrel 75 mg, ticagrelor 90 mg twice daily, or prasugrel 10 mg daily) is mandatory for a minimum of 6 to 12 months, and in certain high-risk cases for up to 24 months. Premature discontinuation of DAPT without cardiology authorization substantially increases the risk of acute in-stent thrombosis, a potentially fatal event causing massive myocardial infarction. Patients must not stop or alter their antiplatelet regimen without explicit cardiologist approval, even if another physician recommends it for a separate procedure.

Material Risks and Potential Complications

Vascular access site complications including hematoma, retroperitoneal hemorrhage (femoral access), radial artery occlusion, arteriovenous fistula, or pseudoaneurysm formation.
Contrast-induced nephropathy (CIN): transient or permanent decline in renal function following iodinated contrast administration, particularly in patients with pre-existing chronic kidney disease or diabetes.
Contrast allergy or anaphylactoid reaction: ranging from mild urticaria to severe bronchospasm and anaphylaxis. Patients with known contrast allergy will receive pre-medication with corticosteroids and antihistamines.
Coronary artery dissection, spasm, or acute closure during wire manipulation, requiring emergency additional stenting or urgent surgical revascularization.
Myocardial infarction (periprocedural MI) due to side branch occlusion, distal embolization of plaque material, or stent thrombosis.
Stroke or transient ischemic attack (TIA) due to air embolism, plaque embolization, or catheter-related thromboembolism (approximately 0.1 to 0.5 percent).
Cardiac arrhythmias including ventricular fibrillation or complete heart block, which may require emergency defibrillation or temporary pacing during the procedure.
Emergency coronary artery bypass graft (CABG) surgery if PCI fails or causes uncontrolled coronary injury (less than 0.5 percent in elective cases).
Death: overall procedural mortality is approximately 0.05 to 0.1 percent for elective PCI; substantially higher in emergency STEMI settings.

Reasonable Alternatives

Optimized medical therapy alone: antianginal medications (long-acting nitrates, beta-blockers, calcium channel blockers), antiplatelet therapy, statins, and ACE inhibitors for stable coronary artery disease. Evidence from the ISCHEMIA trial supports this as equivalent for many stable CAD patients.
Coronary artery bypass graft (CABG) surgery: preferred for left main disease, three-vessel disease with reduced ejection fraction (EF below 35 percent), or complex multi-vessel disease with high SYNTAX score.
Lifestyle modification and risk factor control: supervised cardiac rehabilitation, smoking cessation, dietary intervention, and glycemic control as primary management for borderline lesions.

Expected Benefits

The primary expected benefit of coronary angiography is definitive visualization of the coronary anatomy to guide treatment decisions. If PCI is performed, the intended benefit is restoration of blood flow through the blocked or narrowed artery, which is expected to relieve angina symptoms, reduce myocardial ischemia, and in the setting of acute MI, limit myocardial damage and improve survival. Successful PCI with stent placement aims to restore normal coronary blood flow, reduce angina burden, improve exercise tolerance, and reduce the frequency of hospitalizations for chest pain.

Implant Registry and Stent Identification Card

Following stent implantation, you will receive a stent identification card documenting the stent manufacturer, model, size, and date of implantation. You must carry this card at all times and present it to any healthcare provider or emergency room physician who treats you. This information is critical for future procedures and medication management. Your stent details will also be registered with the facility's implant registry as required by accreditation standards.

Right to Refuse or Withdraw Consent

You have the right to refuse this procedure or withdraw your consent at any time before the procedure begins without penalty or adverse effect on your medical care. Your physician will discuss alternative management strategies with you if you choose not to proceed. In emergency situations (e.g., acute STEMI), delay in proceeding may substantially increase the risk of permanent heart muscle damage or death, and this context will be explained to you.

Questions and Understanding Confirmation

I confirm that I have had the opportunity to read this consent form carefully and ask questions of my cardiologist. All my questions have been answered to my satisfaction. I understand the importance of dual antiplatelet therapy compliance following stent implantation. I believe I am making an informed and voluntary decision.

Language Access and Interpreter Services

If English is not your primary language or if you require assistance communicating, a qualified medical interpreter is available to you at no cost. Please notify your care team immediately if you require interpreter services. You have the right to receive this consent document in your primary language before signing.

Copy of Consent Acknowledgment

I acknowledge that I have been offered a signed copy of this informed consent form for my own records. I understand I may request an additional copy at any time from the facility or clinical records department.

Patient Declaration and Authorization

I have been informed of the nature of coronary angiography and PCI, the expected benefits, the material risks outlined above, and the available alternatives including medical therapy and surgery. I understand the critical importance of adherence to dual antiplatelet therapy following stent implantation and the life-threatening consequences of premature discontinuation. I consent to proceed with the procedure and authorize the cardiologist to perform any additional interventions required to achieve a safe and effective result. I understand that no guarantee of outcome has been made.

Signatures and Verification

Patient / Legally Authorized Representative Signature
Consenting Cardiologist Signature
Witness Signature
Date and Time of Consent
Document ID: CC-PENDING
CONSENTCOLLECT